Calithera Biosciences, Inc. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The following report cites that the company’s drug, “CB-1158, a highly selective, orally bioavailable, small molecule inhibitor of human arginase with nanomolar potency, demonstrated single agent efficacy in animal models.” Read the full document.
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company, which focuses on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA. [Source: MarketWatch]
Company Website: http://www.calithera.com